5 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 5 of 5 clinical reviews.
Inclisiran (Leqvio) is FDA-approved for ASCVD, not familial hypercholesterolemia. Learn the off-label dosing protocol, ORION trial evidence, and how clinicians are using it for HeFH.
Inclisiran cuts LDL-C ~50%, but ORION-4 shows only modest event reduction versus PCSK9 antibodies. See dosing, mechanism, and guideline status.
Inclisiran (Leqvio) is FDA-approved for heterozygous familial hypercholesterolemia and clinical ASCVD requiring additional LDL lowering. This evidence summary reviews the off-label rationale, trial data, and guideline context for using Leqvio in broader ASCVD secondary prevention.
A clinician-focused review of inclisiran (Leqvio) for ASCVD secondary prevention, covering off-label status, LDL-C efficacy data from ORION trials, dosing protocol, and guideline context.
HeFH on max statins is FDA-approved for Leqvio (47.9% LDL-C drop, ORION-9); HoFH use is off-label, with ORION-5 showing about 19.8% reduction.